GLP-1 Diabetes Drugs Poised for Massive Growth, Benefits Beyond Obesity

GLP-1 drugs are gaining popularity for treating obesity and diabetes, with the market forecast to reach $100 billion by 2030.

The potential patient population for GLP-1 drugs could expand significantly if more insurers cover them and they show promise treating other diseases.

Stocks of GLP-1 drug makers Eli Lilly and Novo Nordisk have surged, but further upside depends on increasing supply to meet demand.

Widespread GLP-1 adoption could benefit industries from airlines to medtech and boost U.S. GDP growth.

Biotech companies are leading innovation in new therapies, offering growth potential but also volatility for investors.